For the year to September 2024, Gilead Sciences had an accrual ratio of -0.24. That implies it has very good cash conversion, ...
MarketBeat on MSN7d
Gilead's Stock Surge: What's Fueling the Momentum?Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...
Biopharma giant Gilead Sciences will shut down its office in Seattle's Eastlake neighborhood, the company confirmed to ...
Global biopharmaceutical company Gilead Sciences Inc. (Nasdaq: GILD) is closing its office in Seattle and laying off 72 ...
Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...
Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...
Wolfe Research initiated coverage of Gilead (GILD) with an Outperform rating and $110 price target Gilead’s bread and butter has been ...
Gilead Sciences has underperformed the broader market ... The company’s earnings surprise history is mixed. It beat the consensus estimate in three of the past four quarters while missing ...
Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings estimates and raised its guidance, boosted by demand for its HIV and ...
Wolfe Research initiated coverage of Gilead (GILD) with an Outperform rating and $110 price target Published first on TheFly – the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback